# Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

> **NCT05292053** · PHASE4 · COMPLETED · sponsor: **Baylor Research Institute** · enrollment: 80 (actual)

## Conditions studied

- Copd

## Interventions

- **DRUG:** TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation

## Key facts

- **NCT ID:** NCT05292053
- **Lead sponsor:** Baylor Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2024-09-09
- **Final completion:** 2025-02-09
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05292053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05292053, "Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05292053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*